Urol. praxi, 2014; 15(4): 162-165

Is the current LUTS/BPH therapy sufficient?

MUDr.Libor Zámečník, Ph.D., FEBU, FECSM
Urologická klinika VFN a 1. LF UK, Praha

This article summarizes treatment options for lower urinary tract symptoms in combination with symptoms of overactive bladder.

Keywords: prostate, overactive bladder, hyperplasia, therapy

Published: October 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zámečník L. Is the current LUTS/BPH therapy sufficient? Urol. praxi. 2014;15(4):162-165.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chapple C. Systematic review of therapy for men with overactive bladder. Can Urol Assoc J, 2011; 5(5)(Suppl 2): S143-145. Go to original source... Go to PubMed...
    2. Geirsson G, Fall M, Lindstrom S. Subtypes of overactive bladder in old age. Age Ageing, 1993; 22(2): 125-131. Go to original source... Go to PubMed...
    3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology, 2003; 61(1): 37-49. Go to original source... Go to PubMed...
    4. Záleský M, Zachoval R, Vik V, et al. Léčba hyperaktivity močového měchýře (OAB) u mužů. Urol List 2009; 7(2) 23-30.
    5. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol, 2006; 50(6): 1306-1314; discussion 1314-1315. Go to original source... Go to PubMed...
    6. Sexton CC, Coyne KS, Kopp ZS, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int, 2009; 103(Suppl 3): 12-23. Go to original source... Go to PubMed...
    7. Jumadilova Z, Harris H, Del Aguila M, et al. Agent Selection for Overactive Bladder Patients with and without Documented Comorbid Benign Prostatic Hyperplasia. ICS 2005, Montreal. Abstract 486, č., s.
    8. Hanus T, Zamecnik L, Dolezal T, et al. Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic. Urol Int, 2011; 86,(4): 407-413. Go to original source... Go to PubMed...
    9. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol, 2008; 54(3): 543-562. Go to original source... Go to PubMed...
    10. Kaplan SA, Roehrborn CG, Chancellor M, et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int, 2008; 102(9): 1133-1139. Go to original source... Go to PubMed...
    11. Lee SH, Chung BH, Kim SJ, et al. Initial combined treatment with anticholinergics and alpha-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer Prostatic Dis, 2011; 14(4): 320-325. Go to original source... Go to PubMed...
    12. Greco KA, Mcvary KT. The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res, 2008; 20(Suppl 3): S33-43. Go to original source... Go to PubMed...
    13. Hofner K, Burkart M, Jacob G, et al. Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol, 2007; 25(6): 627-633. Go to original source... Go to PubMed...
    14. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol, 2013; 64(1): 118-140. Go to original source... Go to PubMed...
    15. Van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol, 2013; 64(6): 1003-1012. Go to original source... Go to PubMed...
    16. Drake MJ, Chapple C, Sokol R, et al. Long-term Safety and Efficacy of Single-tablet Combinations of Solifenacin and Tamsulosin Oral Controlled Absorption System in Men with Storage and Voiding Lower Urinary Tract Symptoms: Results from the NEPTUNE Study and NEPTUNE II Open-label Extension. Eur Urol, 2014, Epub 2014/07/30.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.